Bad cholesterol (LDL) combined with a good HbA1c is a common and often misunderstood combination of blood test results. Many people assume that a normal HbA1c — indicating well-controlled blood sugar — means their overall metabolic health is sound. However, LDL cholesterol and HbA1c measure entirely different aspects of health, and elevated LDL can pose a serious cardiovascular risk even when blood glucose is perfectly normal. This article explains what these results mean together, how UK clinical guidance approaches this scenario, and what steps you can take to protect your heart health.

What It Means to Have High LDL Cholesterol but a Normal HbA1c

High LDL cholesterol and a normal HbA1c reflect two separate health dimensions — elevated LDL drives atherosclerosis and cardiovascular risk regardless of blood sugar control.

Receiving blood test results that show elevated LDL (low-density lipoprotein) cholesterol alongside a normal HbA1c can feel confusing. Many people assume that if their blood sugar is well controlled, their overall metabolic health must be in good shape. However, these two markers measure entirely different aspects of your health, and one can be abnormal while the other remains perfectly within range.

LDL cholesterol — often referred to as 'bad cholesterol' — is a type of lipoprotein that carries cholesterol through the bloodstream. When LDL levels are persistently elevated, cholesterol can accumulate within the walls of arteries, contributing to a process called atherosclerosis. This is a key driver of cardiovascular disease, including heart attacks and strokes. Alongside LDL cholesterol, clinicians in the UK also use non-HDL cholesterol (total cholesterol minus HDL cholesterol) as a preferred measure for assessing and monitoring cardiovascular risk, as recommended by NICE.

HbA1c, by contrast, measures your average blood glucose level over the preceding two to three months. A normal HbA1c (below 42 mmol/mol in the UK) indicates that your blood glucose has been well regulated and rules out a diagnosis of diabetes (defined as 48 mmol/mol or above). It does not, however, exclude insulin resistance, which can exist even when HbA1c is within the normal range. It also provides no information about your cholesterol levels or cardiovascular risk from lipid abnormalities.

It is also worth noting that HbA1c may be unreliable in certain situations — for example, in people with anaemia, haemoglobinopathies (such as sickle cell trait), advanced chronic kidney disease (CKD), or during pregnancy. In these circumstances, a fasting plasma glucose or oral glucose tolerance test (OGTT) may be more appropriate.

In short, having a 'good' HbA1c is genuinely reassuring regarding blood sugar control, but it provides no protection against the risks associated with high LDL cholesterol. Both markers need to be considered independently when assessing your overall health picture.

How LDL Cholesterol and HbA1c Measure Different Health Risks

LDL and non-HDL cholesterol assess cardiovascular risk from lipid abnormalities, while HbA1c measures glycaemic control; they operate through entirely separate biological pathways.

Understanding what each test actually measures helps clarify why they can diverge so significantly. A full lipid profile — which includes LDL cholesterol, HDL (high-density lipoprotein) cholesterol, total cholesterol, non-HDL cholesterol, and triglycerides — assesses the balance of fats circulating in your blood. In UK practice, non-fasting lipid samples are acceptable for initial assessment, and non-HDL cholesterol is the preferred marker for monitoring treatment response. Elevated LDL and non-HDL cholesterol are associated with an increased risk of:

• Coronary artery disease

• Peripheral arterial disease

• Ischaemic stroke

• Aortic aneurysm

HbA1c, on the other hand, reflects glycaemic control. It is used to diagnose and monitor type 2 diabetes and to identify non-diabetic hyperglycaemia (NDH) — the UK term for blood glucose levels that are raised but not yet in the diabetic range. A raised HbA1c (48 mmol/mol or above) indicates diabetes; a level between 42 and 47 mmol/mol indicates non-diabetic hyperglycaemia, which carries an increased risk of progressing to type 2 diabetes. A normal result means blood glucose has been well regulated, reducing the risk of conditions such as diabetic nephropathy, retinopathy, and neuropathy.

The two tests operate through entirely separate biological pathways. LDL cholesterol is influenced by dietary fat intake, genetic factors (such as familial hypercholesterolaemia), liver function, and physical activity levels. HbA1c is shaped by carbohydrate metabolism, insulin sensitivity, pancreatic function, and dietary sugar intake. While there is some overlap — for instance, obesity can worsen both — it is entirely possible for someone to have excellent glycaemic control while simultaneously having a lipid profile that poses significant cardiovascular risk.

This distinction is clinically important. Relying on a normal HbA1c as a general indicator of metabolic health may lead to underestimating cardiovascular risk, particularly in individuals with a family history of heart disease or those who are middle-aged or older.

Can You Have Heart Disease Risk Without Diabetes?

Yes — high LDL cholesterol is a well-established independent cardiovascular risk factor; conditions such as familial hypercholesterolaemia can cause very high LDL with a completely normal HbA1c.

Yes — and this is one of the most important messages in cardiovascular medicine. Many people who develop heart disease do not have diabetes. High LDL cholesterol is one of the most well-established independent risk factors for cardiovascular disease, regardless of blood sugar status.

Other significant risk factors that operate independently of HbA1c include:

• Hypertension (high blood pressure)

• Smoking

• Family history of premature cardiovascular disease

• Age and sex (risk increases with age; men are at higher risk at a younger age)

• Chronic kidney disease

• Obesity and physical inactivity

Familial hypercholesterolaemia (FH) is a particularly important genetic condition in which LDL cholesterol is significantly elevated from birth due to a defect in LDL receptor function. People with FH can have a normal HbA1c and no signs of diabetes, yet face a substantially elevated lifetime risk of heart attack if the condition goes untreated. Adults with a total cholesterol above 7.5 mmol/L or an LDL cholesterol above 4.9 mmol/L should be assessed for possible FH and considered for referral to a lipid clinic. NICE guideline CG71 recommends that FH is identified and treated early, often with high-intensity statin therapy, and that cascade testing is offered to first-degree relatives.

In the UK, premature cardiovascular disease is generally defined as a heart attack or coronary artery disease in a male first-degree relative under 55 years of age, or a female first-degree relative under 65 years of age. For FH assessment using the Simon Broome criteria, a myocardial infarction in a first-degree relative under 60 years is a relevant trigger.

Even in the absence of a genetic condition, persistently elevated LDL cholesterol — particularly when combined with other risk factors — warrants clinical attention. Tools such as the QRISK3 calculator, used widely in NHS primary care and endorsed by NICE NG238, estimate a person's 10-year cardiovascular risk by incorporating multiple variables, not just blood sugar. A normal HbA1c will not neutralise a high QRISK3 score driven by elevated LDL and other risk factors.

NHS Guidance on Managing High Cholesterol When Blood Sugar Is Healthy

NICE NG238 recommends QRISK3 cardiovascular risk assessment and statin therapy when 10-year risk is 10% or above, irrespective of HbA1c status.

NICE guideline NG238 (Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification, 2023) provides the current framework for managing cholesterol in UK primary care. It recommends that adults aged 40 to 74 are offered a cardiovascular risk assessment using the QRISK3 tool as part of the NHS Health Check programme (offered every five years). If the 10-year cardiovascular risk is 10% or greater, or if there are specific conditions such as familial hypercholesterolaemia or CKD, treatment is typically recommended regardless of HbA1c status.

For individuals with a normal HbA1c but raised LDL or non-HDL cholesterol, the NHS approach involves:

• Lifestyle modification as a first-line intervention for those at lower risk

• Statin therapy for those with a QRISK3 score of ≥10%, or with conditions such as familial hypercholesterolaemia, CKD, or established cardiovascular disease

• Monitoring of non-HDL cholesterol to assess treatment response, with a target of at least a 40% reduction in non-HDL cholesterol from baseline at three months

• Referral to a lipid specialist if LDL or non-HDL cholesterol remains very high despite treatment, or if FH is suspected

Atorvastatin 20 mg is the preferred first-line statin recommended by NICE for primary prevention of cardiovascular disease in most adults. For secondary prevention (those with established cardiovascular disease), higher-intensity statin therapy — such as atorvastatin 80 mg — is recommended unless contraindicated or not tolerated. All statins used in the UK are approved by the Medicines and Healthcare products Regulatory Agency (MHRA); prescribers and patients should refer to the relevant Summary of Product Characteristics (SmPC) via the electronic Medicines Compendium (emc) for full prescribing information.

Importantly, a normal HbA1c does not remove the indication for statin therapy if cardiovascular risk is elevated. Clinicians are guided to treat lipid abnormalities on their own merits. Patients should be reassured that managing cholesterol proactively — even when blood sugar is healthy — is a well-evidenced strategy for reducing the risk of heart attack and stroke over the long term.

Lifestyle Changes and Treatments That Target LDL Cholesterol

Reducing saturated fat, increasing soluble fibre, and following a Mediterranean-style diet are first-line lifestyle measures; statin therapy remains the most evidence-based pharmacological option for lowering LDL.

Many effective interventions specifically target cholesterol without adversely affecting blood sugar control. Most lifestyle changes that lower LDL also support overall metabolic health.

Dietary modifications are a cornerstone of LDL management:

• Reducing saturated fat (found in fatty cuts of meat, full-fat dairy, butter, and processed foods such as pastries and biscuits) and replacing it with unsaturated fats (olive oil, oily fish, nuts, and seeds)

• Reducing trans fats, found in some processed and fried foods

• Increasing soluble fibre intake through oats, pulses, fruit, and vegetables, which helps reduce LDL absorption in the gut

• Following a Mediterranean-style dietary pattern, which has good evidence for cardiovascular benefit

Note: whilst plant sterols and stanols (available in some fortified foods and supplements) can reduce LDL cholesterol, NICE does not routinely recommend them for cardiovascular disease prevention, and they should not be used as a substitute for evidence-based treatments.

Physical activity is also highly effective. The NHS recommends at least 150 minutes of moderate-intensity aerobic activity per week. Regular exercise raises HDL ('good') cholesterol and can modestly reduce LDL and triglycerides.

Before starting lipid-lowering therapy, it is worth checking for secondary causes of raised cholesterol, such as hypothyroidism, liver disease, nephrotic syndrome, or certain medications. Excess alcohol intake can significantly raise triglycerides and should be addressed if relevant.

When lifestyle changes are insufficient, statin therapy remains the most evidence-based pharmacological option. Statins work by inhibiting HMG-CoA reductase, an enzyme involved in hepatic cholesterol synthesis, thereby reducing LDL production and increasing LDL receptor activity in the liver. It is important to be aware that statins are associated with a small increase in blood glucose and HbA1c, as highlighted in MHRA safety communications. This risk is generally small and is outweighed by the cardiovascular benefits for most people; your GP or pharmacist can discuss this with you. If you experience any suspected side effects from a statin or any other medicine, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

For those who cannot tolerate statins or who do not reach their treatment target on a statin alone, NICE has approved several additional options:

• Ezetimibe (NICE TA385), which reduces intestinal cholesterol absorption, can be used alone or added to a statin

• PCSK9 inhibitors — alirocumab (NICE TA393) and evolocumab (NICE TA394) — for high-risk patients or those with FH who remain above target

• Inclisiran (NICE TA733), a twice-yearly injection that lowers LDL cholesterol, for adults with primary hypercholesterolaemia or mixed dyslipidaemia

• Bempedoic acid with ezetimibe (NICE TA694), an option for adults who are statin-intolerant or not at their treatment target

These options are typically initiated or overseen by a specialist lipid clinic.

When to Speak to Your GP About Your Cholesterol and Blood Sugar Results

Speak to your GP if total cholesterol exceeds 7.5 mmol/L, LDL exceeds 4.9 mmol/L, or you have a family history of premature cardiovascular disease, as early intervention significantly reduces long-term risk.

If you have received blood test results showing elevated LDL or non-HDL cholesterol alongside a normal HbA1c, it is worth discussing these findings with your GP — even if you feel well and have no symptoms. Cardiovascular disease often develops silently over many years, and early intervention is far more effective than treating established disease.

Consider contacting your GP if:

• Your total cholesterol is above 7.5 mmol/L or your LDL cholesterol is above 4.9 mmol/L — these levels may indicate familial hypercholesterolaemia and warrant further assessment

• You have a family history of premature cardiovascular disease (heart attack or coronary artery disease in a male first-degree relative under 55, or a female first-degree relative under 65)

• You have been told previously that you may have familial hypercholesterolaemia

• Your QRISK3 cardiovascular risk score is 10% or above, or you have other significant risk factors such as high blood pressure, CKD, or smoking

• Your triglycerides are very high (levels above 10 mmol/L require urgent assessment due to the risk of acute pancreatitis)

• You are already on cholesterol-lowering medication but your levels remain above your treatment target

Seek urgent medical attention if you develop:

• Chest pain or pressure, particularly with breathlessness or sweating — these may be symptoms of a heart attack and require a 999 call

• Sudden weakness, facial drooping, or speech difficulties — these may indicate a stroke; call 999 immediately

• Severe breathlessness at rest

Your GP may arrange a QRISK3 cardiovascular risk assessment, repeat lipid testing (including non-HDL cholesterol), blood pressure measurement, and a review of your lifestyle and family history. If your risk is elevated, they will discuss the benefits and potential side effects of statin therapy with you, allowing you to make an informed decision.

Regarding HbA1c retesting: the NHS Health Check programme offers a cardiovascular and metabolic health review every five years for adults aged 40 to 74. Your GP may recommend earlier retesting if you have risk factors for type 2 diabetes, such as being overweight, having non-diabetic hyperglycaemia, or having high blood pressure. Keeping both your cholesterol and blood sugar under review gives you and your healthcare team the most complete picture of your long-term health. Do not hesitate to ask your GP to explain your results in full; understanding your numbers is the first step towards managing them effectively.

Frequently Asked Questions